Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinpanemab Phase 1 SAD Study in Healthy Volunteers and Early Parkinson's Disease
NCT02459886Phase 1Completed
- Sponsor
- Biogen
- Start
- Jul 2015
- Primary completion
- Nov 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cinpanemab in Parkinson's disease (PD) (7 cohorts), sponsored by Biogen. Primary endpoints: Adverse events/serious adverse events at 20 Weeks, Columbia Suicide Severity Rating Scale at 20 Weeks and 1 more. Started Jul 2015; status: completed.
02
Drugs
cinpanemab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02459886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02459886.